je.st
news
Tag: cancer
International Scientific Forum on Alcohol Research Critique 162: What is the Association between Alcohol Consumption and Cancer?
2015-04-13 16:58:00| Daily beverage news and comment - from just-drinks.com
Three major papers on the association of alcohol consumption and cancer have recently been published. ISFAR forum members considered that all were well-done, and presented valuable new information on the topic.
Tags: forum
international
research
association
Setting a new record for cancer research
2015-04-12 23:11:53| Food - Topix.net
The fifth annual initiative to support breast cancer research at The Hormel Institute raised at least $189,000 dollars. That tops 2014's record high of $162,000.
Tags: research
record
setting
cancer
Luke Perry's Discusses His Crusade Against Cancer
2015-04-09 15:47:44| Chemicals - Topix.net
The actor lost a friend this year to colon cancer, and his childhood friend Chad Schrack's wife is a survivor of the disease. "I can't imagine anything Chad would ask me to do that I wouldn't help him with, so I was happy to jump in and help," the actor, 48, tells PEOPLE about how he got involved with Fight Colorectal Cancer's "One Million Strong" campaign, which encourages people to get screened for the disease.
Tags: cancer
discusses
luke
crusade
Patent dispute settlement to benefit Penn cancer therapy partnership
2015-04-08 13:56:58| Biotech - Topix.net
Novartis Pharmaceutical Corp. settled its patent dispute with Juno Therapeutics, removing any potential litigation obstacles from the immunotherapy partnership between Novartis and the University of Pennsylvania. The Wall Street Journal reported Novartis will pay Seattle-based Juno $12.25 million, plus undisclosed future milestone payments and royalties, to resolve the dispute.
Tags: benefit
partnership
cancer
therapy
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for the Treatment of Advanced Prostate Cancer
2015-04-08 13:30:05| Merck.com - Product News
Dateline City: PRINCETON, N.J., and KENILWORTH, N.J. KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). Language: English read more
Sites : [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] next »